Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride

• Published in: Cardiovascular diabetology Vol. 20; no. 1; pp. 237 - 12
• Main Authors: Jendle, J., Hyötyläinen, T., Orešič, M., Nyström, T.
• Format: Journal Article
• Language: English
• Published: England BioMed Central 17.12.2021; BMC
• Subjects: Aged; Antidiabetics; Bile acids; Biomarkers - blood; Body weight; Carbohydrate metabolism; Cardiovascular disease; Cardiovascular diseases; Ceramide; Cholesterol; Chromatography, High Pressure Liquid; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Drug Therapy, Combination; Esters; Fatty acids; Fatty liver; Female; Gender; Generalized linear models; Glimepiride; GLP-1 receptor agonist; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Glucose metabolism; Glycerol; Heart attacks; Heart failure; Hemoglobin; High-performance liquid chromatography; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Incretins - adverse effects; Incretins - therapeutic use; Insulin resistance; Lipid metabolism; Lipidomics; Lipids; Lipids - blood; Liraglutide; Liraglutide - adverse effects; Liraglutide - therapeutic use; Liver; Liver diseases; Male; Mass spectrometry; Mass spectroscopy; Metabolites; Metabolome; Metabolomics; Metformin; Metformin - therapeutic use; Middle Aged; Myocardial infarction; Open source software; Original Investigation; Quality control; Scientific imaging; Spectrometry, Mass, Electrospray Ionization; Sphingolipids; Standard deviation; Sulfonylurea Compounds - adverse effects; Sulfonylurea Compounds - therapeutic use; Time Factors; Treatment Outcome; Tryptophan; Type 2 diabetes; United States > US; Sweden; Myocardial infarction; Type 2 diabetes; Glimepiride; Metabolomics; Ceramide; Lipidomics; GLP-1 receptor agonist; Liraglutide

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a tr...